Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine

Clinical and Vaccine Immunology

Volumn 22, Issue 8, 2015, Pages 943-948

  Nygård, Mari ^a   Saah, Alfred ^b   Munk, Christian ^c   Tryggvadottir, Laufey ^d,e   Enerly, Espen ^a   Hortlund, Maria ^f   Sigurdardottir, Lara G ^d,e   Vuocolo, Scott ^b   Kjaer, Susanne K ^c,g   Dillnerf, Joakim ^f  

^a CANCER REGISTRY OF NORWAY   (Norway)

^b MERCK RESEARCH LABORATORIES   (United States)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^d ICELANDIC CANCER REGISTRY   (Iceland)

^e UNIVERSITY OF ICELAND   (Iceland)

^f KAROLINSKA INSTITUTE   (Sweden)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VIRUS ANTIBODY; WART VIRUS VACCINE; IMMUNOGLOBULIN G;

ADULT; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DENMARK; DRUG SAFETY; DRUG SCREENING; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; ICELAND; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; INCUBATION TIME; NORWAY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SINGLE BLIND PROCEDURE; SWEDEN; VACCINATION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; ADOLESCENT; BLOOD; DOUBLE BLIND PROCEDURE; FOLLOW UP; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; SERUM; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; PAPILLOMAVIRUS INFECTIONS; SERUM; TIME FACTORS; YOUNG ADULT;

EID: 84939555411     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00133-15     Document Type: Article

References (26)

1. Ault KA. 2007. Effect of prophylactic human papillomavirus L1 viruslike-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369:1861-1868. http://dx.doi.org/10.1016/S0140-6736(07)60852-6.
2. U.S. Food and Drug Administration. 2006. Approval letter: human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant. U.S. Food and Drug Administration, Washington, DC.
3. Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, Brotons M, Mena M, Cosano R, Munoz J, Bosch J, de Sanjosé S, Castellsagué X. Human papillomavirus and related diseases in the world. Summary Report 2015-04-08. ICO Information Centre on HPV and Cancer (HPV Information Centre). Accessed 24 June 2015. http://www.hpvcentre.net/statistics/reports/XWX.pdf.
4. Mariani L, Vici P, Suligoi B, Checcucci-Lisi G, Drury R. 2015. Early direct and indirect impact of quadrivalentHPV(4HPV) vaccine on genital warts: a systematic review. Adv Ther 32:10-30. http://dx.doi.org/10.1007/s12325-015-0178-4.
5. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. 2003. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157:218-226. http://dx.doi.org/10.1093/aje/kwf180.
6. Moscicki AB, Schiffman M, Kjaer S, Villa LL. 2006. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine 24(Suppl):S3, S42-S51. http://dx.doi.org/10.1016/j.vaccine.2005.01.101.
7. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. 2007. Human papillomavirus and cervical cancer. Lancet 370:890-907. http://dx.doi.org/10.1016/S0140-6736(07)61416-0.
8. Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, De Grandi P. 2003. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 95:1128-1137. http://dx.doi.org/10.1093/jnci/djg018.
9. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, Lowy DR, Schiller JT. 2007. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13:857-861. http://dx.doi.org/10.1038/nm1598.
10. Lowy DR, Schiller JT. 2006. Prophylactic human papillomavirus vaccines. J Clin Invest 116:1167-1173. http://dx.doi.org/10.1172/JCI28607.
11. Stanley M. 2008. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 109:S15-S21. http://dx.doi.org/10.1016/j.ygyno.2008.02.003.
12. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E. 2007. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25:4931-4939. http://dx.doi.org/10.1016/j.vaccine.2007.03.049.
13. Brown DR, Garland SM, Ferris DG, Joura E, Steben M, James M, Radley D, Vuocolo S, Garner EI, Haupt RM, Bryan JT. 2011. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin 7:230-238. http://dx.doi.org/10.4161/hv.7.2.13948.
14. Villa LL. 2007. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. Int J Infect Dis 11(Suppl): S17-S25. http://dx.doi.org/10.1016/S1201-9712(07)60017-4.
15. Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, Brown M, Smith J, Chirmule N, Barr E, Jansen KU, Esser MT. 2005. Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 12:959-969.
16. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT. 2003. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed Luminex assay. Clin Diagn Lab Immunol 10:108-115.
17. Opalka D, Matys K, Bojczuk P, Green T, Gesser R, Saah A, Haupt R, Dutko F, Esser MT. 2010. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol 17:818-827. http://dx.doi.org/10.1128/CVI.00348-09.
18. Kjaer S, Nygård M, Dillner J, Marshall B, Hansen B, Sigurdardottir L, Hortlund M, Tryggvadóttir L, Saah A. 2015. HPV infection and related cancers: translating research innovation into improved practice, p 15, 19. In Eurogin 2015 International Multidisciplinary Congress, Sevilla, Spain. Eurogin, Paris, France.
19. Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch X, Dillner J, Kurman RJ, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Lu S, Vuocolo S, Hesley TM, Haupt RM, Barr E. 2008. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalentHPVvaccine. Vaccine 26:6844-6851. http://dx.doi.org/10.1016/j.vaccine.2008.09.073.
20. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsague X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF, Jr, Reisinger KS. 2006. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118:2135-2145. http://dx.doi.org/10.1542/peds.2006-0461.
21. Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, Bryan J, Vuocolo S, Haupt RM, Saah A. 2011. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 105:28-37. http://dx.doi.org/10.1038/bjc.2011.185.
22. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E. 2006. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24:5571-5583. http://dx.doi.org/10.1016/j.vaccine.2006.04.068.
23. Stanley M. 2010. Potential mechanisms for HPV vaccine-induced longterm protection. Gynecol Oncol 118:S2-S7. http://dx.doi.org/10.1016/j.ygyno.2010.04.002.
24. Brown D, Muller M, Sehr P, Pawlita M, Seitz H, Rubio I, Antonello J, Radley D, Roberts C, Saah A. 2014. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18. Vaccine 32:5880-5887. http://dx.doi.org/10.1016/j.vaccine.2014.08.004.
25. Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, Brotherton JM. 2012. Human papillomavirus vaccine introduction-the first five years. Vaccine 30(Suppl):F139-F148. http://dx.doi.org/10.1016/j.vaccine.2012.05.039.
26. Nygård M, Kjaer S, Dillner J, Marshall JB, Hansen BH, Sigurdardottir LG, Hortlund M, Tryggvadottir L, Saah A. 2013. Long-term immunogenicity, safety and effectiveness of Gardasil in the Nordic countries, p OC 6-3. In Eurogin 2013 International Multidisciplinary Conference, Florence, Italy. Eurogin, Paris, France.